Business Context and Reporting Period
This Form 6-K filing by Ping An Biomedical Co., Ltd. covers the month of February 2026, with a report date of February 12, 2026. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of securities.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or existing debt levels. The only financial data disclosed relates to the new capital raise:
- Shares Issued: 100,000,000 ordinary shares
- Purchase Price: $0.04 per share
- Total Aggregate Proceeds: $4,000,000
Material Changes
On February 9, 2026, the Company entered into securities purchase agreements with certain accredited investors. This represents a material change in the Company's capital structure through the issuance of new ordinary shares. The closing of this transaction is expected to occur within three business days of the agreement date, subject to customary conditions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond standard regulatory disclosures. The transaction is exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. The issued shares are subject to transfer restrictions and cannot be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the execution of the Securities Purchase Agreement (Exhibit 10.1) to confirm closing conditions.
- Confirm the actual closing date and receipt of the $4,000,000 in proceeds.
- Review the updated cap table to assess the dilution impact of the 100,000,000 new shares.
- Check for any subsequent filings regarding the use of proceeds from this private placement.